An Open-label, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Combination Chemotherapy With DoceTaxel(Detaxel) and Oxaliplatin(Oxalitin)in Recurrent or Metastatic Breast Cancer
Overview
- Phase
- Phase 2
- Intervention
- docetaxel/ oxaliplatin
- Conditions
- Recurrent Breast Cancer
- Sponsor
- Korean Breast Cancer Study Group
- Enrollment
- 51
- Locations
- 1
- Primary Endpoint
- overall response rate
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer.
Detailed Description
Recent therapeutic developments, such as the introduction of new cytotoxic agents (taxanes, platinum, liposomal anthracyclines, etc) have resulted in constant improvements in treatment efficacy and consequently in recurrent or metastatic outcome. This single arm, multicenter phase II study was designed to evaluate the response rate, toxicity, progression free survival of docetaxel and oxaliplatin in patients with recurrence or metastatic breast cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women aged : 20\~70 years
- •WHO (ECOG) performance status 0-2
- •Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline
- •patients had previously not received chemotherapy of recurrent or metastatic lesion.
- •Have given written informed consent and are available for prolonged follow-up
Exclusion Criteria
- •Patients with previous chemotherapy for recurrent breast cancer
- •Breast cancer recurrence within 12 months after taxane treatment
- •Her-2/neu expression breast cancer
- •Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.
- •Brain metastasis
- •uncontrolled infection, medically uncontrollable heart disease
- •other serious medical illness or prior malignancies
- •Pregnant or lactating women were excluded.
Arms & Interventions
docetaxel/ oxaliplatin
All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
Intervention: docetaxel/ oxaliplatin
Outcomes
Primary Outcomes
overall response rate
Time Frame: 2 years
Secondary Outcomes
- progression free survival(2 years)
- toxicity(2 years)
- quality of life(2 years)